These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17943082)

  • 1. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy.
    Torres DD; Rossini M; Manno C; Mattace-Raso F; D'Altri C; Ranieri E; Pontrelli P; Grandaliano G; Gesualdo L; Schena FP
    Kidney Int; 2008 Feb; 73(3):327-33. PubMed ID: 17943082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy.
    Stangou M; Alexopoulos E; Papagianni A; Pantzaki A; Bantis C; Dovas S; Economidou D; Leontsini M; Memmos D
    Nephrology (Carlton); 2009 Sep; 14(6):613-20. PubMed ID: 19143943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors of complete remission in primary glomerulonephritis.
    Chanrat E; Worawichawong S; Radinahamed P; Sathirapongsasuti N; Nongnuch A; Assanatham M; Udomsubpayakul U; Kitiyakara C
    Cytokine; 2018 Apr; 104():1-7. PubMed ID: 29414320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type1 and transforming growth factor β1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy.
    Segarra-Medrano A; Carnicer-Caceres C; Valtierra-Carmeno N; Agraz-Pamplona I; Ramos-Terrades N; Jatem Escalante E; Ostos-Roldan E
    Nefrologia; 2017; 37(5):531-538. PubMed ID: 28946966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy.
    Grandaliano G; Gesualdo L; Bartoli F; Ranieri E; Monno R; Leggio A; Paradies G; Caldarulo E; Infante B; Schena FP
    Kidney Int; 2000 Jul; 58(1):182-92. PubMed ID: 10886563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary Glomerulonephritis.
    Worawichawong S; Worawichawong S; Radinahamed P; Muntham D; Sathirapongsasuti N; Nongnuch A; Assanatham M; Kitiyakara C
    Kidney Blood Press Res; 2016; 41(6):997-1007. PubMed ID: 27988512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease.
    Satirapoj B; Dispan R; Radinahamed P; Kitiyakara C
    BMC Nephrol; 2018 Sep; 19(1):246. PubMed ID: 30241508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy.
    Ranieri E; Gesualdo L; Petrarulo F; Schena FP
    Kidney Int; 1996 Dec; 50(6):1990-2001. PubMed ID: 8943482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic indices and therapy in IgA nephropathy: toward a solution.
    Ballardie FW; Cowley RD
    Kidney Int; 2008 Feb; 73(3):249-51. PubMed ID: 18195693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease.
    Wu L; Li XQ; Chang DY; Zhang H; Li JJ; Wu SL; Zhang LX; Chen M; Zhao MH
    Nephrol Dial Transplant; 2020 Feb; 35(2):291-297. PubMed ID: 30357416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Urinary Epidermal Growth Factor to Creatinine Ratio to Predict 24-Hour Urine Epidermal Growth Factor and Interstitial Kidney Fibrosis in Patients with IgA Nephropathy.
    Segarra A; Carnicer C; Jatem E; Martin M; Molina M; Perich C; Martinez C
    Clin Lab; 2019 Jun; 65(6):. PubMed ID: 31232037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor and monocyte chemotactic peptide-1: potential biomarkers of urinary tract obstruction in children with hydronephrosis.
    Madsen MG; Nørregaard R; Palmfeldt J; Olsen LH; Frøkiær J; Jørgensen TM
    J Pediatr Urol; 2013 Dec; 9(6 Pt A):838-45. PubMed ID: 23228281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.
    Zittema D; van den Brand JA; Bakker SJ; Wetzels JF; Gansevoort RT
    Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i146-i153. PubMed ID: 28057871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression.
    Yang X; Ou J; Zhang H; Xu X; Zhu L; Li Q; Li J; Xie D; Sun J; Zha Y; Li Y; Tian J; Liu Y; Hou FF
    Am J Kidney Dis; 2020 Mar; 75(3):384-393. PubMed ID: 31606236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes of urinary monocyte chemotactic protein 1 and epidermal growth factor and their correlations with clinicopathology in idiopathic membranous nephropathy patients].
    Zheng S; Zhao ZH; Liu ZJ; Wang DH; Liu DW; Liu ZS
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(16):1230-1234. PubMed ID: 32344494
    [No Abstract]   [Full Text] [Related]  

  • 16. Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios.
    Ngamjanyaporn P; Worawichawong S; Pisitkun P; Khiewngam K; Kantachuvesiri S; Nongnuch A; Assanatham M; Sathirapongsasuti N; Kitiyakara C
    PLoS One; 2022; 17(3):e0263778. PubMed ID: 35271583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
    Peters HP; van den Brand JA; Wetzels JF
    Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
    Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
    Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
    Komatsu H; Fujimoto S; Sato Y; Hara S; Yamada K; Morita S; Eto T
    J Nephrol; 2005; 18(6):690-5. PubMed ID: 16358226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.